At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...
The Chosun Ilbo on MSN
Early CAR-T therapy boosts blood cancer survival rates
T therapy was used as a last resort in third-line treatment for patients who had failed standard therapies like chemotherapy ...
This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...
As CAR T-cell therapy reaches community oncology, practice leaders discuss the challenges of payer hurdles, single case ...
Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...
A novel in vivo CD19 CAR-T therapy achieved complete remission in a DLBCL patient without lymphodepletion, showing sustained efficacy over three months. The therapy demonstrated safety, with no ...
While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results